European Commission

UK's MHRA Approves Adjuvant Lynparza for BRCA-Mutant, High-Risk Early Breast Cancer

Novartis' Scemblix Nets European Approval for Subset of CML Patients

Roche Gets Expanded CE Mark for Ventana PD-L1 Assay to ID NSCLC Patients for Tecentriq

Merck, AstraZeneca Net European Approval for Adjuvant Lynparza in BRCA-Mutated Early Breast Cancer

EMA's CHMP Recommends Restricting Third-Line Ovarian Cancer Indication for Clovis' Rubraca

Gilead's Tecartus Gets EMA CHMP Recommendation in Advanced ALL

Bristol Myers Squibb's Opdualag Gets EMA CHMP Recommendation for Biomarker-Selected Melanoma

Byondis, Medac File for European Approval of SYD985 for HER2-Positive Breast Cancer

Legend Biotech Shutters Trial of CD4-Directed CAR T-Cell Therapy for T-Cell Lymphoma

European Commission Approves Gilead Sciences' Yescarta for Follicular Lymphoma Patients

European Commission Approves Novartis MET Inhibitor Tabrecta for Advanced NSCLC

European Commission Approves Keytruda in Early-Stage Triple-Negative Breast Cancer

Novartis Nabs European Approval for Kymriah in Follicular Lymphoma

Merck Nabs European Approvals for Keytruda in Cervical Cancer, Biomarker-Defined Solid Tumors

EMA's CHMP Recommends Novartis' Tabrecta for Previously Treated NSCLC With METex14 Skipping Mutation

Bristol Myers Squibb's Breyanzi Approved in Europe for Lymphoma Patients

European Commission Approves Immunocore's T-Cell Receptor Therapy Kimmtrak in Uveal Melanoma

EMA's CHMP Issues Positive Recommendation for Merck's Keytruda in PD-L1-Expressing Cervical Cancers